

DAFTAR PUSTAKA

- Angelucci, A., Delle Monache, S., Cortellini, A., Di Padova, M., & Ficarella, C. (2018). "Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms19010299>
- Baba, H., Baba, Y., Uemoto, S., Yoshida, K., Saiura, A., Watanabe, M., Kokudo, N. (2015). Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: Results of a multicenter study. *Oncotarget*. <https://doi.org/10.18632/oncotarget.5227>
- Balacescu, O., Sur, D., Cainap, C., Visan, S., Cruceriu, D., Manzat-Saplacan, R., ... Irimie, A. (2018). The impact of miRNA in colorectal cancer progression and its liver metastases. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms19123711>
- Brouwer, N. P. M., Bos, A. C. R. K., Lemmens, V. E. P. P., Tanis, P. J., Hugen, N., Nagtegaal, I. D., ... Verhoeven, R. H. A. (2018). An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. *International Journal of Cancer*. <https://doi.org/10.1002/ijc.31785>
- Ballinger, A. and Anggiansah, C. (2007). Colorectal cancer. *BMJ*, 335(7622), pp.715-718. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001051/> [Accessed 7 Mar. 2019].
- Brundu S, F. A. (2015). Polarization and Repolarization of Macrophages. *Journal of Clinical and Cellular Immunology*. <https://doi.org/10.4172/2155-9899.1000319>
- Bunni, J., Shelley-Fraser, G., Stevenson, K., Oltean, S., Salmon, A., Harper, S. J., ... Bates, D. O. (2015). Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxx_b) in colorectal cancer patients predicts tumour VEGF-A ratios. *American Journal of Cancer Research*.
- Cagir, B. (2018). *Rectal Cancer: Practice Essentials, Background, Anatomy*. [online] Emedicine.medscape.com. Available at: <https://emedicine.medscape.com/article/281237-overview#a1> [Accessed 7 Mar. 2019].
- Canavese, M., Ngo, D. T. M., Maddern, G. J., Hardingham, J. E., Price, T. J., & Hauben, E. (2017). Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. *International Journal of Cancer*. <https://doi.org/10.1002/ijc.30567>
- Center for Disease Control and Prevention (CDC). (2016). Colorectal (colon) cancer : What are the risk factor for colorectal cancer?.

https://www.cdc.gov/cancer/colorectal/basic_info/risk_factors.htm [Accessed 7 Mar. 2019]

Ellis, L., Abrahão, R., McKinley, M., Yang, J., Somsouk, M., Le Marchand, L., ... Shariff-Marco, S. (2018). Colorectal cancer incidence trends by age, stage, and Racial/Ethnic Group in California, 1990-2014. *Cancer Epidemiology Biomarkers and Prevention*, 27(9), 1011–1018. <https://doi.org/10.1158/1055-9965.EPI-18-0030>

Fearnley, G. W., Smith, G. A., Odell, A. F., Latham, A. M., Wheatcroft, S. B., Harrison, M. A., ... Ponnambalam, S. (2014). Vascular endothelial growth factor a-stimulated signaling from endosomes in primary endothelial cells. In *Methods in Enzymology*. <https://doi.org/10.1016/B978-0-12-397925-4.00016-X>

Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012). Colorectal carcinoma: Pathologic aspects. *Journal of Gastrointestinal Oncology*, 3(3), 153–173. <https://doi.org/10.3978/j.issn.2078-6891.2012.030>

George, M. L., Tutton, M. G., Janssen, F., Arnaoutz, A., Abulafi, A. M., Eccles, S. A., & Swift, R. I. (2001). VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. *Neoplasia*. <https://doi.org/10.1038/sj.neo.7900186>

Greb, R. R., Maier, I., Wallwiener, D., & Kiesel, L. (1999). Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause breast tissue but not in breast cancer lesions. *British Journal of Cancer*. <https://doi.org/10.1038/sj.bjc.6690681>

Gonzalez R. (2019). Adenocarcinoma of colon. PathologyOutlines.com. <http://www.pathologyoutlines.com/topic/colontumoradenocarcinoma.html>. [Accessed August 27th, 2019].

Hauptman, N., & Glavač, D. (2017). Colorectal Cancer Blood-Based Biomarkers. *Gastroenterology Research and Practice*. <https://doi.org/10.1155/2017/2195361>

Hayashi, H., Arao, T., Matsumoto, K., Kimura, H., Togashi, Y., Hirashima, Y., ... Yamada, Y. (2014). Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. *Oncotarget*. <https://doi.org/10.18632/oncotarget.1811>

Huusko, J., Merentie, M., Dijkstra, M. H., Ryhänen, M. M., Karvinen, H., Rissanen, T. T., ... Ylä-Herttuala, S. (2010). The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice. *Cardiovascular Research*. <https://doi.org/10.1093/cvr/cvp382>

Iarc., I. A. for R. on C. W. H. O. (2012). GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. *Globocan*. <https://doi.org/10.1002/ijc.27711>

- Ilic, I., Jankovic, S., & Ilic, M. (2016). Bevacizumab combined with chemotherapy improves survival for patients with metastatic colorectal cancer: Evidence from meta analysis. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0161912>
- Iovino, F., Ferraraccio, F., Orditura, M., Antoniol, G., Morgillo, F., Cascone, T., ... De Vita, F. (2008). Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. *Cancer Investigation*. <https://doi.org/10.1080/07357900701560612>
- Komite Penanggulangan Kanker Nasional. (2017). Panduan nasional penatalaksanaan kanker kolorektal.
- Kumar, V., Abbas, A. K., & Aster, J. C. (2018). Robbins Basic Pathology, 10th ed. In *Elsevier Saunders*. <https://doi.org/10.1016/j.aquatox.2009.12.021>
- Kut, C., Mac Gabhann, F., & Popel, A. S. (2007). Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer. *British Journal of Cancer*. <https://doi.org/10.1038/sj.bjc.6603923>
- Lech, G., Słotwiński, R., Słodkowski, M., & Krasnodębski, I. W. (2016). Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. *World Journal of Gastroenterology*. <https://doi.org/10.3748/wjg.v22.i5.1745>
- Lin, J., & Redies, C. (2012). Histological evidence: Housekeeping genes beta-actin and GAPDH are of limited value for normalization of gene expression. *Development Genes and Evolution*. <https://doi.org/10.1007/s00427-012-0420-x>
- Liu, J., & Tao, C. (2019). Overexpression of miRNA-125a-5p inhibits the growth and angiogenesis of hepatocellular carcinoma by regulating the expression of VEGF-A. *Biotechnology & Biotechnological Equipment*, (33:1), 1116–1125. <https://doi.org/10.1080/13102818.2019.1640073>
- Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods*. <https://doi.org/10.1006/meth.2001.1262>
- Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular basis of colorectal cancer. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJMra0804588>
- Miura, N., Hasegawa, J., & Shiota, G. (2008). Serum messenger RNA as a biomarker and its clinical usefulness in malignancies. *Clinical Medicine: Oncology*. <https://doi.org/10.4137/cmo.s379>
- Nasser, M., & Sawicki, P. (2009). Institute for Quality and Efficiency in Health Care: Germany. *Issue Brief (Commonwealth Fund)*.

- Newton, K. F., Newman, W., & Hill, J. (2012). Review of biomarkers in colorectal cancer. *Colorectal Disease*. <https://doi.org/10.1111/j.1463-1318.2010.02439.x>
- Nolan, T., Huggett, J., & Sanchez, E. (2013). Good Practice Guide for the Application of Quantitative PCR (qPCR). *National Measurement System*.
- PERABOI. (2010). *Panduan Penatalaksanaan Kanker Solid*. 98–128. Retrieved from <http://kanker.kemkes.go.id/guidelines/PPKKolorektal.pdf>
- Sa-nguanraksa, D., & O-charoenrat, P. (2012). The role of vascular endothelial growth factor A polymorphisms in breast cancer. *International Journal of Molecular Sciences*. <https://doi.org/10.3390/ijms131114845>
- Sharifi, N., Ghaffarzadegan, K., Ayatollahi, H., Shakeri, M. T., Sadeghian, M. H., & Azari, J. B. (2009). Evaluation of angiogenesis in colorectal carcinoma by CD34 immunohistochemistry method and its correlation with clinicopathologic parameters. *Acta Medica Iranica*.
- Shijubo, N., Uede, T., Kon, S., Maeda, M., Segawa, T., Imada, A., ... Abe, S. (1999). Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. *American Journal of Respiratory and Critical Care Medicine*. <https://doi.org/10.1164/ajrccm.160.4.9807094>
- Stockmann, C., Doedens, A., Weidemann, A., Zhang, N., Takeda, N., Greenberg, J. I., ... Johnson, R. S. (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. *Nature*. <https://doi.org/10.1038/nature07445>
- Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Horiike, Y., Matsusaka, S., ... Yamaguchi, T. (2016). Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. *Oncotarget*. <https://doi.org/10.18632/oncotarget.9187>
- Von Keudell, G., & Larson, R. A. (2016). Journal of clinical oncology. *Journal of Clinical Oncology*. <https://doi.org/10.1200/JCO.2013.50.0140>
- Yang, L., & Zhang, Y. (2017). Tumor-associated macrophages: from basic research to clinical application. *Journal of Hematology & Oncology*. <https://doi.org/10.1186/s13045-017-0430-2>
- Yang, X., Qiu, J., Kang, H., Wang, Y., & Qian, J. (2018). miR-125a-5p suppresses colorectal cancer progression by targeting VEGFA. *Cancer Management and Research*. <https://doi.org/10.2147/CMAR.S161990>
- Yoshida, N., Nakanishi, M., Inoue, K., Yasuda, R., Hirose, R., Naito, Y., ... Kishimoto, M. (2018). Pure Well-Differentiated Adenocarcinoma Is a Safe Factor for Lymph Node Metastasis in T1 and T2 Colorectal Cancer: A Pilot Study. *Gastroenterology Research and Practice*. <https://doi.org/10.1155/2018/8798405>

Zhang, S. D., McCrudden, C. M., Meng, C., Lin, Y., & Kwok, H. F. (2015). The significance of combining VEGFA, FLT1, and KDR expressions in colon cancer patient prognosis and predicting response to bevacizumab. *OncoTargets and Therapy*. <https://doi.org/10.2147/OTT.S80518>